Drug Profile
Research programme: biodefence therapeutics - Callisto
Alternative Names: 6343 peptide; Anti Toxic Shock antibody - Callisto; ATS antibody - Callisto; Biodefense therapeutics - Callisto; TSS MabLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Callisto Pharmaceuticals
- Developer Synergy Pharmaceuticals Inc
- Class Monoclonal antibodies; Peptides; Vaccines
- Mechanism of Action T cell activation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Staphylococcal infections; Streptococcal infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Staphylococcal-infections in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Streptococcal-infections in USA
- 17 Jan 2013 Callisto Pharmaceuticals has been merged into Synergy Pharmaceuticals Inc